ClinicalTrials.gg
RecruitingNCT06817434SEST-MOYAUpdated Feb 10, 2025

Study on Evaluating the Effectiveness of Statins in the Treatment of Moyamoya Disease

An observational study in Moyamoya Disease, sponsored by Beijing Tiantan Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2025-02-10.

Sponsored by Beijing Tiantan Hospital · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 10 months ago, but the record still lists the study as recruiting.
  • Started Dec 2024; still recruiting 1 year 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
330
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 14 studies in Moyamoya Disease by Beijing Tiantan Hospital — 10 open to participants now, 10 under way, none of them phase 3. Moyamoya Disease · Beijing Tiantan Hospital.

Planned enrollment
7th of 11
330 · median 350
Started
2024
with 2 others
Observational
11 of 14
8 open now
Registered
9th of 14
by date

Among the 14 studies in Moyamoya Disease by Beijing Tiantan Hospital, this one is the 7th largest by planned enrollment of the 11 observational ones that give a count, is one of 3 that started in 2024, is one of 11 observational ones, and was the 9th registered.

Moyamoya Disease

62 studies on the registry are indexed under Moyamoya Disease; 30 are open to participants now.

Browse Moyamoya Disease studies →

Open to participants now

10 of the 14 studies in Moyamoya Disease by Beijing Tiantan Hospital are open now, in 1 country. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 10 open studies →

Where they have run

Who these studies take

Of the 22 Moyamoya Disease studies recruiting now, 9 (41%) set no upper age limit and 10 (45%) stop at 75 or younger; 9 take children under 18; 5 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Moyamoya Disease by Beijing Tiantan Hospital, or all of them as a file.
02

Study summary

The purpose of this study is to investigate the effectiveness of statins in the treatment of moyamoya disease based on multimodal magnetic resonance imaging.

03

Conditions studied

  • Moyamoya Disease

Browse trials for

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients diagnosed with MMD in Beijing Tiantan Hospital will be recruited. Eligibility will be determined through a checklist of inclusion and exclusion criteria.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. The imaging examination meets the diagnostic criteria for moyamoya disease;
  2. Sign the form;
  3. Age ≥18 years old;
  4. Baseline mRS score ≤2 points;
  5. The patient receives revascularization/conservative treatment;
  6. There is at least 1 imaging follow-up result.

Exclusion criteria

Exclusion Criteria:

  1. Patients with atherosclerosis, diseases, meningitis, Down syndrome, cranial trauma, or those who have undergone radioactive head irradiation, as these conditions may lead to secondary cerebrovascular disease and contribute to the development of Moyamoya syndrome;
  2. Individuals under the age of 18;
  3. Participants who refuse to take part in this study;
  4. Pregnant patients;
  5. Those with concurrent intracranial aneurysms, cerebrovascular malformations, brain tumors, or hydrocephalus;
  6. A history of stroke occurring more than three months prior to the diagnosis of Moyamoya disease;
  7. Individuals with a history of coronary heart disease or previous cardiovascular and cerebrovascular surgical interventions, including cerebral revascularization, intracranial artery stent implantation, carotid artery stenting, endarterectomy, coronary artery bypass grafting, or coronary stent implantation;
  8. Allergies to contrast media;
  9. Patients with missing imaging data or whose image quality cannot be analyzed;
  10. Individuals who refuse or are unable to undergo imaging follow-up;
  11. Patients receiving other types of lipid-lowering drug treatments.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
330 participants (estimated)
Target follow-up
18 Months
Patient registry
Yes
Biospecimen retention
Samples with dna

Interventions

  • DrugRevascularization/Conservative management

    Revascularization/Conservative management

06

What researchers measure

Primary outcomes

  1. Rate of participants experiencing cerebrovascular events (TIA, ischemic stroke, or hemorrhagic stroke)

    The occurrence of cerebrovascular events, including TIA, ischemic stroke, or hemorrhagic stroke, will be assessed over an 18-month follow-up period.

    Time frame: 18 months during follow-up

Secondary outcomes

  1. Changes in Neurological Function (mRS, NIHSS) at 12 and 18 Months After Treatment

    The mRS and NIHSS will be used to assess changes in neurological function at 12 and 18 months after treatment.

    Time frame: 12 and 18 months during follow-up

  2. Changes in Cognitive Function (MoCA, MMSE) at 12 and 18 Months After Treatment

    The MoCA and MMSE will be used to evaluate changes in cognitive function at 12 and 18 months after treatment.

    Time frame: 12 and 18 months during follow-up

  3. Structural Remodeling of the Internal Carotid Artery Terminal and Middle Cerebral Artery Wall at 12 and 18 Months After Treatment

    High-resolution magnetic resonance vessel wall imaging will be used to evaluate structural remodeling changes in the internal carotid artery terminal and middle cerebral artery wall at 12 and 18 months after treatment.

    Time frame: 12 and 18 months during follow-up

  4. Changes in Cerebral Blood Perfusion at 12 and 18 Months After Treatment

    ASL will be used to assess cerebral blood perfusion changes at 12 and 18 months after treatment.

    Time frame: 12 and 18 months during follow-up

  5. Rate of New Cerebral Infarcts at 12 and 18 Months After Treatment

    The occurrence of new cerebral infarcts at 12 and 18 Months after treatment will be evaluated using MRI.

    Time frame: 12 and 18 months during follow-up

  6. Hemodynamic Changes at the Internal Carotid Artery Terminal at 12 and 18 Months After Treatment

    4D-Flow MRI and hemodynamic analysis will be used to evaluate changes in hemodynamics at the internal carotid artery terminal at 12 and 18 months after treatment.

    Time frame: 12 and 18 months during follow-up

  7. Changes in Blood Lipid Levels at 12 and 18 Months After Treatment

    Blood lipid levels will be measured and compared at 12 and 18 months after treatment.

    Time frame: 12 and 18 months during follow-up

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2024 (actual). Primary completion is estimated for Dec 2025, 12 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 26, 2025
First posted
Feb 10, 2025
StartActual
Dec 15, 2024
Primary completionEst.
Dec 31, 2025
CompletionEst.
Dec 31, 2026
Last update
Feb 10, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 10, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06817434
Responsible party
Sponsor
First posted
Feb 10, 2025
Start date
Dec 15, 2024
Primary completion
Dec 31, 2025 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Feb 10, 2025

Study contacts

Qian Zhang
Contact
zhangqianchina@yahoo.com
8613120012579
Chaofan Zeng
Contact
zchf723@163.com
8613693276138

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion